Common Equity: The sum of all common equity items.
Klotho Neurosciences, Inc. (GRML) had Common Equity of $9.46M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-10.55M |
|
-- |
|
-- |
|
$7.15M |
|
$-7.15M |
|
$-3.41M |
|
$-10.55M |
|
$-10.55M |
|
$-10.55M |
|
$-10.55M |
|
$-10.55M |
|
$-10.55M |
|
$-7.15M |
|
$-7.15M |
|
48.49M |
|
48.49M |
|
$-0.22 |
|
$-0.22 |
|
| Balance Sheet Financials | |
$7.29M |
|
-- |
|
$2.30M |
|
$9.59M |
|
$0.08M |
|
-- |
|
$0.05M |
|
$0.13M |
|
|
Common Equity |
$9.46M |
$7.16M |
|
$9.46M |
|
72.54M |
|
| Cash Flow Statement Financials | |
$-5.89M |
|
-- |
|
$13.00M |
|
$0.06M |
|
$7.18M |
|
$7.11M |
|
$1.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
95.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.89M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-111.50% |
|
-147.29% |
|
-109.99% |
|
-111.50% |
|
$0.13 |
|
$-0.12 |
|
$-0.12 |
|